Observational studyMedicine2025
Evaluation of portal venous flow velocity before and after direct acting antiviral therapy in chronic hepatitis C: A cohort study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the changes in portal venous flow velocity before and after direct-acting antiviral (DAA) therapy in patients diagnosed with chronic hepatitis C (CHC). A total of 53 CHC patients (36 males, 17 females; mean age 61.8 ± 7.7 years) treated with DAA at the Gastroenterology Department of our institution were included, along with 55 healthy controls matched by age and sex. Portal vein flow velocity was measured using Doppler ultrasonography, before and after treatment. Biochemical parameters, aspartate aminotransferase to platelet ratio, and fibrosis-4 scores were also analyzed. The mean pretreatment portal vein velocities in patients before treatment were 12.1 m/s and 17.5 m/s in the control healthy individuals (P < .001). DAA therapy resulted in a 100% sustained viral response. The posttreatment velocity increased significantly to 18 m/s (P < .001). Aspartate aminotransferase and alanine aminotransferase levels were significantly decreased (P < .001), while serum albumin levels were increased (P = .008). Although the platelet count increased, the change was not statistically significant (P = .232). Significant improvements were observed in aspartate aminotransferase to platelet ratio and fibrosis-4 scores (P < .001). The cirrhotic and non-cirrhotic subgroups demonstrated significant increases in portal flow velocity and decreased fibrosis values. DAA therapy in CHC patients also improved portal hemodynamics and noninvasive fibrosis markers, suggesting a broader impact on liver health and portal circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.